Vepdegestrant is an experimental estrogen receptor degrader that works via proteolysis targeting chimera. It is developed for advanced estrogen receptor positive breast cancer. From Wikipedia
Enrolling 624 previously treated patients at the American Society of Clinical Oncology meeting in Chicago, the trial delivered a more than three-month progression-free survival advantage over Faslodex, prompting Arvinas to cancel two other planned late-stage studies.
